Zum Hauptinhalt springen
Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Handbook of Office-Based Buprenorphine Treatment of Opioid Use Disorder -

Handbook of Office-Based Buprenorphine Treatment of Opioid Use Disorder

Buch | Softcover
395 Seiten
2017 | Second Edition
American Psychiatric Association Publishing (Verlag)
978-1-61537-083-2 (ISBN)
CHF 106,50 inkl. MwSt
  • Versand in 15-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
A guide for the addition of buprenorphine treatment into existing psychiatric practices and other primary care settings. The potential to improve the lives of patients with the disease of opioid addiction is great, and this book offers concrete and practical advice for managing patients in an office-based setting.
As the epidemic of opioid misuse and overdose deaths grows in the United States, practical information on evidence-based treatment of opioid use disorder (OUD) becomes increasingly important. This second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder offers just that: accessible and applicable guidance for anyone interested in learning more about prescribing buprenorphine.

Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout the book, make it easier for readers to retain knowledge and integrate it into their practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice.
Among the updates in this new edition are chapters that address other pharmacotherapies useful in treating OUD, including methadone and naltrexone, as well as OUD treatment in the context of women’s health and pregnancy. As an added bonus, this edition can also be used to complete the 8 hours of qualifying training required for the buprenorphine waiver. By a thorough reading of the material covered in the chapters of this book and successful completion of the posttest, physicians can meet the buprenorphine waiver training requirement.

John A. Renner Jr., M.D., is Professor of Psychiatry at Boston University School of Medicine and Associate Chief of Psychiatry of the VA Boston Healthcare System in Boston, Massachusetts. Petros Levounis, M.D., M.A., is Professor and Chair of the Department of Psychiatry at Rutgers New Jersey Medical School and Chief of Service at University Hospital in Newark, New Jersey. Anna T. LaRose, M.D., is Instructor in Psychiatry at Boston University Medical School and Staff Psychiatrist at the VA Boston Healthcare System in Boston, Massachusetts.

Chapter 1. Opioid Use Disorder in America: History and Overview
Chapter 2. General Opioid Pharmacology
Chapter 3. Efficacy and Safety of Buprenorphine
Chapter 4. Patient Assessment
Chapter 5. Clinical Use of Buprenorphine
Chapter 6. Buprenorphine Treatment in Office-Based Settings
Chapter 7. Psychosocial and Supportive Treatment
Chapter 8. Prevention, Diversion, and Logistics
Chapter 9. Methadone, Naltrexone and Naloxone
Chapter 10. Psychiatric Co-Morbidity
Chapter 11. Medical Comorbidity
Chapter 12. Acute and Chronic Pain

Erscheinungsdatum
Zusatzinfo 1 chart, 31 figures, 28 tables
Verlagsort VA
Sprache englisch
Maße 152 x 228 mm
Gewicht 655 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
ISBN-10 1-61537-083-8 / 1615370838
ISBN-13 978-1-61537-083-2 / 9781615370832
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Zwischen Normvariante, Persönlichkeitsstörung und …

von Ludger Tebartz van Elst

Buch | Softcover (2022)
Kohlhammer (Verlag)
CHF 49,95